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Background: Five-year survival rates for resected stage I adenocar-
cinoma approach 100%. Given previous studies describing the pro-
longed indolent natural history of ground-glass lesions suspicious 
for early adenocarcinoma, our purpose in this study was to determine 
if outcomes were different among patients who were observed for 
radiographic and biopsy suspected early adenocarcinoma compared 
with those who were resected immediately.
Methods: We identified 63 patients with no prior history of lung 
adenocarcinoma who had undergone computer tomography–guided 
fine-needle aspiration of ground-glass opacities with cytology con-
cerning for new early adenocarcinoma between January 2002 and 
December 2011. We compared the clinical outcomes of patients who 
were resected after abnormal cytology results and those who opted 
for watchful waiting.
Results: Sixteen patients elected to observe their ground-glass nod-
ules despite having suspicious cytology results, whereas 47 opted 
for immediate resection. Of the 16 observed patients, six (37.5%) 
ultimately demonstrated growth or increase solid component of the 
ground-glass nodule. Five of these patients elected for definitive ther-
apy by surgical resection or radiation. There were no occurrences of 
distant metastasis or lung cancer–associated deaths in the observed 
group. Of the 47 resected patients, two developed metastatic disease, 
five developed new cancers in remaining lung, and three developed 
progression in existing ground-glass nodules.
Conclusions: Ground-glass lesions that were observed after 
biopsy did not demonstrate any increased rates of metastasis or 
 cancer-related deaths and delayed resection does not seem to have a 
negative effect on outcomes.
Key Words: Lung cancer, Needle biopsy, Early detection, Lung nod-
ule, Fine-needle aspiration.
(J Thorac Oncol. 2014;9: 685–691)
Bronchioloalveolar carcinoma (BAC) is an imprecise term that causes confusion regarding the true nature of the lung 
lesions that receive this designation. In 2011, the International 
Association for the Study of Lung Cancer/American Thoracic 
Society/European Respiratory Society proposed the abandon-
ment of term BAC and reclassified lesions as atypical adeno-
matous hyperplasia (AAH), adenocarcinoma in situ (AIS), 
minimally invasive adenocarcinoma (MIA), and lepidic pre-
dominant adenocarcinoma.1 These lesions are now considered 
to be on the spectrum of the same disease, here termed early 
adenocarcinoma.
Multiple series have correlated radiographic and patho-
logic findings, and it has been learned that pure ground-glass 
opacities (GGOs) or those with more than 50% GGO with a 
part-solid component have long doubling times.2–6 Pure GGOs 
are, on average, 15% benign, 5% adenomatous hyperplasia, 
40% to 60% AIS, and 10% invasive adenocarcinoma.3,7–9 
Increasing solid component, history of lung cancer, female 
gender, and larger size correlate with the presence of invasive 
adenocarcinoma.7,10,11
A role for computer tomography (CT)-guided  fine-needle 
aspiration (FNA) in the evaluation of GGOs is not universally 
accepted because its utility is uncertain. First, cytologic fea-
tures in the setting of GGOs are often subtle, and cytopatholo-
gists may end up rendering a diagnosis of atypical or suspicious 
rather than definitively malignant. Second, because FNA does 
not allow for complete histologic evaluation, even when malig-
nant cells are identified, cytopathologists cannot distinguish 
between preinvasive, minimally invasive, and invasive adeno-
carcinoma with a meaningful degree of certainty.12–14
Currently, primary treatment of AIS and MIA is the 
same as that of invasive adenocarcinoma, namely, surgical 
resection for early-stage disease if the patient is fit for surgery. 
However, sublobar (wedge and segmentectal) resections are 
becoming more common for AIS/MIA compared with stan-
dard lobectomy for invasive adenocarcinoma.15,16  Long-term 
survival is near 100% in surgical case series,17–20 but it is 
unclear if survival is related to resection itself or that these 
lesions are indolent in nature and would likely never progress 
to invasive disease.
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Given the highly favorable outcomes of early adenocar-
cinoma (AAH and AIS/MIA) after resection, the aim of this 
study was to explore the natural history of untreated early ade-
nocarcinoma. Paradoxically, this is difficult to answer because 
to make a definitive diagnosis of AIS or MIA, there must be 
a surgically resected specimen. We hypothesized that patients 
with a combination of radiographic findings of ground-glass 
nodules who underwent CT-guided FNA lung biopsy with 
cytologically atypical or suspicious findings could serve as a 
surrogate for early adenocarcinoma (meant to encompass the 
spectrum of AAH, AIS, and MIA). Since there is uncertainty 
over how to proceed when cellular atypia is noted on cytology, 
some patients will inevitably proceed to definitive treatment 
with surgery and some will elect for serial observation.
We evaluated a retrospective cohort of patients with 
lesions that are radiographically and cytologically concerning 
for early adenocarcinoma, comparing outcomes for patients 
who were resected versus those who were observed.
PATIENTS AND METHODS
With approval from the Institutional Review Board at 
Weill Cornell Medical center (Protocol #903010284), we 
reviewed the electronic medical records for all patients who 
underwent a CT-guided FNA lung biopsy (CT-FNA) of a 
pulmonary nodule at New York Presbyterian Hospital, Weill 
Cornell Medical Center, during a 10-year period (January 
2002–December 2011).
To be included in the study, subjects had to have a 
CT of the chest that showed a “nonsolid” or “ground-glass” 
nodule of which the greatest dimension was less than or 
equal to 30 mm.3
Subjects were also required to have a cytology report 
from the CT-FNA which read “adenocarcinoma with bronchi-
oloalveolar features,” “BAC,” “suspicious for BAC,” “atypical 
cells,” or “abnormal cells” (Table 1). Patients also had to have 
at least one follow-up appointment or CT scan after 3 months 
of the cytology report.
Patients were excluded if the FNA specimen received 
an unqualified diagnosis of “adenocarcinoma” (which we con-
sidered to more likely represent invasive adenocarcinoma), 
“inflammation,” “reactive,” “benign,” or “necrotic debris.” If 
the patient was also being sent for FNA of a nodule suspi-
cious for infection by physician documentation or if they were 
being treated with chemotherapy for metastatic cancer, they 
were also excluded. Patients were also excluded if they had a 
history of lung adenocarcinoma (Table 2). Concurrent atypi-
cal FNA results in another nodule were included. For resected 
patients, treatment had to be within 6 months of the FNA, oth-
erwise the patients were classified as observed.
Outcomes of interest were progression of the primary 
nodule, defined as increase in the overall size by at least 2 mm 
in diameter, as previously described11 or increase in the solid 
component, progression of other ground-glass nodules, or the 
appearance of new suspicious nodules, that is, solid nodules 
more than 10 mm in size or GGO more than 15 mm in size on 
more than one follow-up examination, or evidence for meta-
static disease.
FNA Technique
The technique for needle biopsy was the same as was 
previously described.21 For all FNAs, 1% lidocaine was admin-
istered into the subcutaneous tissues and pleural surfaces for 
local anesthesia. A General Electric Lightspeed CT scanner 
(GE Healthcare, Waukesha, WI) was used, with CT param-
eters set at 120 kVp for tube voltage, 20 to 40 mAs for tube 
current, and 1.25 to 2.5 mm for slice thickness, depending on 
patient body habitus and nodule size. Under CT guidance, 
a 22-gauge Westcott needle (BD Medical, Franklin Lakes, 
NJ) was advanced into the pulmonary lesion. Samples were 
obtained and provided to an onsite cytologist who determined 
specimen adequacy. Additional samples were acquired using 
a new 22-gauge needle as deemed necessary and/or feasible 
by the cytologist and radiologist. A post-FNA CT image was 
obtained to document the development of a pneumothorax.
Data Collection
A chart review was performed to extract relevant clini-
cal information on all patients who met the study criteria. 
Clinical variables included history of prior malignancy, smok-
ing status, number of pack years, recent (within 3 mo) posi-
tron emission tomography (PET), and results of recent CT of 
nodule of interest. Follow-up imaging and clinical documen-
tation were also reviewed and noted. Clinical information col-
lected included progression of disease based on CT and death 
from any cause and/or from lung cancer.
Radiologic variables analyzed for each patient included 
the size of the lesion of interest and the presence of other 
(multiple) lung nodules.
Cytology reports were reviewed and were classified into 
two categories. Group 1 included patients with “atypical cells” 
or “abnormal cells.” Group 2 included patients with a report 
reading “adenocarcinoma with bronchioloalveolar features,” 
“favor BAC,” or “suspect BAC” (Table 1).
TABLE 1.   Targeted Study Population of Biopsy-Suspected Early Adenocarcinoma
Cytology FNA
Radiographic
Nonsolid Part-Solid Solid
Benign Benign Benign Benign
Atypical Suspected early adenocarcinomaa Suspected early adenocarcinoma Indeterminate
Adenocarcinoma Suspected early adenocarcinomaa Adenocarcinoma Adenocarcinoma
aGroups of patients identified with current study definitions.
FNA, fine-needle aspiration.
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Pathology reports were reviewed of patients who had 
resected nodules, including what type of resection (lobec-
tomy, segmentectomy, or wedge resection) was performed. In 
all cases, the diagnosis was based on structure alone. Since 
many of the resections occurred before the 2011 consensus 
reclassification of BAC, the pathology reports were revised 
to fit into the new classification. The reports, and in some 
cases original slides, were reviewed by an expert patholo-
gist to classify lesions into the more updated categories of 
AAH, MIA, AIS, or IA. The pathologist was blinded to the 
outcomes of each case.
Progression of primary nodules, progression of remain-
ing nodules, development of metastatic disease, and mortality 
data were gathered through chart review of physician notes 
and follow-up CT images. Mortality data were collected based 
on the last date of physician contact or chart note documenting 
a patient’s death. Follow-up was determined by a review of the 
patients’ medical record. A determination of last clinic visit 
and imaging study was also performed to determine any evi-
dence of recurrence. Patients were deemed “lost to  follow-up” 
once they stopped returning for routine visits, the reason for 
which is unknown.
Statistical Analysis
Categorical variables were analyzed using a chi-square 
test. For continuous variables (age, number of pack years, 
standardized uptake value score on PET, and nodule size), 
an unpaired two-sided Student’s t test was performed. Odds 
ratios were also calculated using Cox regression analysis. 
 Kaplan-Meier curves, log rank tests, were created to dem-
onstrate progression of disease. Two-sided p-values less than 
0.05 were considered significant. The statistical analysis was 
performed using IBM SPSS statistics, Version 19.
RESULTS
We identified 63 patients who had pure GGOs and had 
CT-FNA showing cells concerning for early adenocarcinoma. 
Forty-seven of these patients underwent resection; 16 patients 
were observed. Resections included wedge (n = 10), segmen-
tectomy (n = 11), lobectomy (n = 25), or combination (n = 1).
Baseline characteristics of the patients are found in 
Table 3. Age, sex, body mass index, tobacco use, history of 
cancer, forced expiratory volume in 1 second, and size of the 
nodule were similarly matched between groups. PET and 
average standardized uptake value were not statistically dif-
ferent between groups. FNA diagnoses falling into group 2 
were more likely to result in resection compared with those 
FNA diagnoses falling into group 1 (p = 0.003).
Of the 47 resected patients, 6% were AAH, 23% were 
AIS, 17% were MIA, and 53% were IA as determined by his-
topathology after resection.
Risk factors associated with progression of disease for 
treated and observed groups are outlined in Table 4. Tobacco use, 
nodule size greater than 15 mm, body mass index, and forced 
expiratory volume in 1 second values did not impact the risk of 
progression. Final pathology result of invasive adenocarcinoma 
was not significantly associated with risk of disease progression.
From the 16 patients who elected observation, six 
patients demonstrated local progression of their disease: 
four demonstrated significant growth in the primary nodule 
and two demonstrated increasing solid component (Table 5). 
Of the six patients who progressed, four underwent surgical 
resection, one underwent definitive radiation therapy, and one 
declined further intervention. The final pathology on five of 
the six patients was invasive adenocarcinoma (one patient did 
not have a repeat biopsy). There were no cases where evidence 
of metastasis to regional lymph nodes, mediastinal lymph 
nodes, or distant organs was observed. There were no cases of 
death attributable to lung cancer in the observed group.
Of the 47 patients who went for immediate resection, 10 
patients demonstrated progression, three developed progres-
sion of remaining nodules, five developed new primary lesions 
in remaining lung, and two developed evidence for metastatic 
disease (Table 6). There was one death in the treated group 
from brain metastases. The patients were followed after the 
time of FNA for an average of 45 months in the resected group 
and 34 months in the observed (p = 0.21).
TABLE 2.  Inclusion and Exclusion Criteria Based on Cytologic, Radiographic, and Clinical Findings
Inclusion Exclusion
Cytology Group 1 Necrotic debris
  Atypical bronchioalveolar proliferation Benign “epithelial cells and histiocytes”
  Atypical (glandular, epithelial, or bronchial) cells Reactive (unless atypical)
  Abnormal cells Adenocarcinoma
Group 2 Inflammation
  Adenocarcinoma with BAC features PCP/AFB+/fungal elements
  Suspicious/favor/suspect BAC Cavitation
Radiology Size <30 mm of largest nodule on CT scan Solid
Pure ground-glass opacity or part-solid Suspicion for infection based on clinical history
Clinical Must have follow-up records with outcome documented (repeat CT scans/physicians 
note) for at least 1 yr
Treatment with chemotherapy
History of lung adenocarcinoma or concurrent 
adenocarcinoma at the time of biopsy
BAC, bronchioloalveolar adenocarcinoma; CT, computed tomography.
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DISCUSSION
This study reports the outcomes of patients who were 
observed after CT detected ground-glass nodules and FNA 
biopsies were suspicious for early adenocarcinoma. Based 
on the data collected in this study, lesions that were observed 
after biopsy did not demonstrate any increased rates to metas-
tasis or cancer-related deaths after a mean follow-up of 34 
months. While 37.5% of these patients continued to have local 
growth of their nodules ultimately resulting in referral for sur-
gery, delayed resection appeared to have no negative effect 
on their outcome. Conversely, patients referred for immedi-
ate resection within 6 months paradoxically demonstrated a 
higher rate of metastatic disease, development of new primary 
lesions, or progression of remaining nodules compared with 
patients who were observed. Because this was a retrospective 
study and the two groups were not randomized, it is possible 
that the resected group represents a more aggressive form of 
the disease, which would explain the higher observed rate of 
metastasis and progression seen in this group. Indeed, “atypi-
cal” FNA results were more common in the observed group 
and likely contributed to the decision to observe rather than 
resect the lesions when compared with a more concerning 
report. Nevertheless, the safe outcome in the observed group 
heightens the concern that resecting early adenocarcinomas 
has little impact on the underlying disease.
Of note, 70% of the resected patients had final pathol-
ogy results that were consistent with either minimally invasive 
or invasive adenocarcinoma. However, only six out of the 16 
observed patients demonstrated change in size and/or den-
sity during the subsequent period of observation. This lack of 
TABLE 3.  Baseline Characteristics
Characteristics Total Treated Observed p
Total number 63 47 16
Age of patients (yr)
  Mean 67.8 66.9 70.3 0.220
  Range 44–88 44–82 55–88
Sex—no. of patients (%)
  Male 17 (27%) 11 (23%) 6 (37.5%) 0.333
  Female 46 (73%) 36 (77%) 10 (62.5%)
Risk factors—no. of patients (%)
  Tobacco use 54 (86%) 40 (85%) 14 (87.5%) 0.999
  History of cancer 12 (20%) 8 (18%) 4 (27%) 0.479
Radiography—no. of patients (%)
  Size of nodule on CT scan (mm)
   Median 12.0 11.0 14.0 0.415
   Range 3–26 4–26 3–22
Size group
  ≤10 mm 26 (41%) 21 (45%) 5 (31%) 0.288
  11–20 mm 29 (46%) 19 (40%) 10 (63%)
  21–30 mm 8 (13%) 7 (15%) 1 (6%)
PET study completed 32 25 7
Average SUV 1.1 1.1 1.2 0.844
Number of nodules
  Single nodule 38 (60%) 29 (62%) 9 (56%) 0.700
  Multiple nodules 25 (40%) 18 (38%) 7 (44%)
Cytology
  Atypical 27 (43%) 15 (32%) 12 (75%) 0.003
  Suspicious/favor BAC, malignant cells 36 (57%) 32 (68%) 4 (25%)
Pulmonary function testsa
  FEV1 ≥ 80% 52 (87%) 41 (89%) 11 (79%) 0.380
  FEV1 50–79% 7 (12%) 4 (9%) 3 (21%)
  FEV1 31–49% 1 (2%) 1 (2%) 0 (0%)
  FEV1 ≤ 30% 0 (0%) 0 (0%) 0 (0%)
BMI
  ≥30 4 (6.5%) 4 (9%) 0 (0%) 0.565
  <30 58 (93%) 42 (91%) 16 (100%)
aTwo patients were excluded from analysis in observed group because no PFT data were available.
CT, computed tomography; PET, positron emission tomography; SUV, standardized uptake value; BAC, bronchioloalveolar carcinoma; FEV1, forced expiratory volume in 1 
second; BMI, body mass index.
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growth in these forms of early adenocarcinoma lends support 
to the idea that these GGOs are indolent findings and not true 
carcinomas. Therefore, GGOs detected by CT screening, even 
with positive cytology for adenocarcinoma, should be viewed 
with caution as it may represent over diagnosis.
Our study had an overall higher rate of progression for 
pathologic stage IA than is generally reported. A possible rea-
son for this is that patients were referred for biopsy usually 
after the radiographic lesion demonstrated growth potential, 
therefore selecting for more aggressive disease. This can be 
supported by the fact that the resected group had more “sus-
picious” initial cytology results, also increasing their risk of 
progression.
Although we did observe an increase in rates of meta-
static disease in the resected group, no difference in mortality 
was observed. There were only two deaths in the 5-year period, 
one in the observed group and one in the resected group. This 
low mortality rate reflects the slow growth rate and indolent 
nature of early adenocarcinoma as well as the fact that our 
relatively small sample size was not powered to detect a dif-
ference. Nevertheless, this lack of mortality benefit from early 
treatment suggests that observation maybe reasonable for 
some patients for whom surgery is higher risk, depending on 
their age and medical comorbidities.
The role of CT-FNA of GGOs and part-solid lesions is 
controversial. Ground-glass lesions are often observed with 
repeat CT over time to avoid unnecessary surgery on nod-
ules which may be from infection or transient inflammation. 
However, repeat scanning may cause increased radiation expo-
sure and cost. ACCP guidelines recommend surgical resection 
of GGOs as the principle method of diagnosis22,23; however, 
this is not always feasible if medical comorbidity increases 
surgical risk. Although CT-FNA is not used in every institution 
for ground-glass nodules suspicious for cancer, we believe it 
provides supplementary data that are useful in helping clini-
cians determine how to treat patients. Accuracy of CT-FNA 
for GGOs is reported to be approximately 80%.12 Although 
ACCP guidelines recommend core biopsy or histopathology 
TABLE 4.  Risk Factors for Progression
Independents Variables
Univariate Predictors
OR (95% CI) p
Age (yr) 1.06 (0.95–1.18) 0.309
Gender
  Male Reference
  Female 2.18 (0.43–11.13) 0.348
BMI
  ≥30 Reference
  <30 1.08 (0.13–8.91) 0.943
FEV1 (%) 0.99 (0.96–1.03) 0.871
History of cancer
  No Reference
  Yes 1.22 (0.23–6.64) 0.817
Tumor size (mm) 0.96 (0.84–1.09) 0.521
Number of nodules
  Single Reference
  Multiple 1.98 (0.55–7.14) 0.300
Histopathological diagnosis
  Noninvasive adenocarcinoma Reference
  Invasive adenocarcinoma 2.70 (0.56–13.07) 0.217
p-value < 0.200 is included the multivariate analysis.
OR, odds ratio; CI, confidence interval; BMI, body mass index; FEV1, forced 
expiratory volume in 1 second.
TABLE 5.  Outcomes of Observed Patients Who Progressed
Patients/Nodules Cancer History
Initial Biopsy 
Date Initial FNA
Repeat Biopsy 
Date Clinical Course Outcome
1. 69F/single h/o breast cancer November 2006 LLL, 17 mm; 
GGO
May 2011 Nodule increased size to 27 mm, SUV 
of 3.1. Resected pathology T1b 
adenocarcinoma
Alive as of July 2012
2. 59F/single Concurrent 
atypical cells in 
LUL, underwent 
lobectomy on 
November 2009
September 2009 RUL, 23 mm; 
GGO
June 2010 Increase in size of nodule by 1.5 cm in 
7 mo. Repeat FNA was suspicious for 
adenocarcinoma but continued to be 
followed. Twenty-four months later, 
nodule enlarged to 5 cm and became 
part solid—received XRT to lesion
Alive July 2012
3. 71M/single None October 2003 RUL, 19 mm; 
GGO
July 2005 Nodule enlarged in 2005 and repeat 
FNA showed BAC. Underwent RUL 
lobectomy
Alive June 2005
4. 77F/single None December 2007 RUL, 16 mm; 
GGO
September 2010 Increased to 19 mm and FNA showed 
AIS. Underwent wedge resection
Alive August 2011
5. 62F/multi None September 2005 RLL, 27 mm; 
GGO
November 2008 Repeat CT with same size in November 
2008 but new part-solid component  
and PET SUV 3.6
Deceased on February 
2009 from unknown 
cause
6. 68F/multi None July 2007 LUL, 16 mm; 
GGO
February 2010 FNA repeated given increase 
solid component which showed 
adenocarcinoma. Resected
Alive July 2012
FNA, fine-needle aspiration; GGO, ground-glass opacity; SUV, standardized uptake value; BAC, bronchioloalveolar carcinoma; CT, computed tomography; PET, positron emission 
tomography.
690 Copyright © 2014 by the International Association for the Study of Lung Cancer
Gulati et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 5, May 2014
to diagnose suspicious GGOs in patients who cannot undergo 
resection, CT-FNA provides important data on the presence 
of a malignancy or benign etiologies. It is noteworthy that the 
predominant pathology of resected nodules in our study was 
invasive adenocarcinoma. This corroborates the notion that 
adenocarcinoma can have especially subtle cytologic features 
on lung FNA, and this in turn suggests a tendency for under-
diagnosis. In addition, we observed no serious adverse effects 
as a result of CT-FNA. A preoperative diagnosis also may be 
helpful in surgical treatment planning. At the time of CT-FNA, 
ground-glass lesions may be marked or tagged before surgery, 
thus permitting localization in these lesions that are difficult to 
find by inspection or palpation intraoperatively, thus avoiding 
missing the lesion and repeat operations.
Strengths of our study include the combination of 
radiologic and cytologic evidence suspicious for early ade-
nocarcinoma. Previous similar studies have evaluated pro-
gression of unresected GGOs without concurrent cytology. 
These studies likely include a significant number of patients 
with benign inflammation as the cause for radiographic 
findings, which may resolve over time and bias the results 
to favor observation. Limitations of this study include its 
retrospective nature, small patient population, and low 
mortality in both groups over 5 years. With an increase in 
metastatic disease in the resected population, our results 
pose a provocative question about the utility of resection in 
GGOs; however, a much larger population should be studied 
to determine if our results are applicable to all GGOs. In 
addition, the nature of this study led to ascertainment bias. 
Progression-free survival is known to be long in GGOs sus-
picious for early adenocarcinoma as documented over time 
by CT scan. However, our patient population was selected 
from those who had FNA of the lesion. Many of these 
patients had nodules for years, and only when there was an 
increase in the size of the lesion or the number of nodules 
was the FNA performed and treatment decision made. If 
FNAs had been done at an earlier stage,  progression-free 
survival would likely be longer than we reported for those 
observed. However, it is important to note that the diagnos-
tic yield of FNA is decreased in early lesions.12,24,25
This study demonstrates that early resection of a GGO 
after a positive FNA may not reduce the rates of progression 
or development of metastatic disease. However, given the 
small number of patients in this study, it is difficult to make 
definitive recommendations about the optimal timing of sur-
gery for an enlarging GGO with a CT-FNA suspicious for an 
early adenocarcinoma. The role of surgery for GGOs with 
suspicious cytology would best be answered in a randomized 
clinical trial. Based on current available evidence, if patients 
are too high risk for surgery or refuse, it may be acceptable to 
continue to observe the nodule even if FNA was positive given 
the slow and indolent growth of these lesions.
TABLE 6.  Outcomes of Resected Patients Who Progressed
Patients/
Nodules
Cancer  
History Date
Initial  
FNA Surgery Clinical Course Outcome
1. 62F/multi None April 2008 RUL, 16 mm RUL wedge resection 
May 2008
Increase in size of other GGOs by 0.5 cm over 
1 yr and increase in part solid component 
of others. Further increase of RLL nodule 
by 1 cm in 1 yr. Underwent RLL for T1NO 
adenocarcinoma January 2010
Alive June 2010
2. 78F/multi Hodgkins  
2003 s/p 
chemotherapy
October 2007 LLL, 14 mm LLL lobectomy 
December 2007
Follow-up CT showed enlarging anterior 
mediastinal lymph node from 1.4 × 1 cm to 
1.6 × 1.1 cm. PET SUV of 4.1. Biopsy-proven 
adenocarcinoma. Referred for chemotherapy 
and XRT
Alive December 2010
3. 70F/single None September 
2005
RML, 12 mm RML lobectomy 
September 2005
New RLL adenocarcinoma diagnosed in 
November 2007, stage IIIA. Resected, 
chemotherapy and XRT given
Alive March 2009 
with progression of 
disease, metastases
4. 74F/multi None March 2007 RUL, 19 mm RUL lobectomy  
April 2007
New 3–9 mm GGOs found on repeat CT scan in 
November 2010. Followed
Alive May 2011
5. 75F/multi Hodgkin’s 
lymphoma
December 
2004
LUL, 17 mm LUL lobectomy 
January 2005
Had growth of RUL GGO, diagnosed with 
adenocarcinoma. Underwent wedge resection. 
Recurrence again, received XRT
Alive May /2013
6. 62F/multi None July 2002 LLL, 17 mm LLL segmentectomy 
September 2002
RML nodule grew 4 mm in 2009 follow-up CT, 
adenocarcinoma and brain mets October 2009
Alive September 2011
7. 73F/multi Uterine October 2004 LUL, 17 mm LUL lobectomy 
November 2004
Increase in size of other nodules 3–6 mm over 
8 yr
Alive February 2013
8. 73M/single None August 2010 RUL, 14 mm RUL lobectomy  
August 2010
New 6–7 mm GGOs noted on follow-up CT scan 
2012
Alive July 2012
9. 67M/single None May 2002 LLL, 21 mm LLL wedge  
June 2002
Developed LLL GGO in 2009. Underwent LLL 
lobectomy for T4N0M0 adenocarcinoma
Alive June 2013
10. 75M/multi None August 2002 RUL, 21 mm RUL lobectomy 
October 2002
Developed recurrent LUL IB adenocarcinoma 
2010. Underwent lingulectomy
Alive December 2011
FNA, fine-needle aspiration; GGO, ground-glass opacity; CT, computed tomography; PET, positron emission tomography; SUV, standardized uptake value.
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